This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
CHICAGO, April 17, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced the closing of its public offering of 8,222,500 shares of common stock at a public offering price of $7.00 per share, before underwriting discounts, including 1,072,500 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price less the underwriting discount.
BofA Merrill Lynch, Credit Suisse Securities (USA) LLC and Jefferies LLC acted as joint book-running managers for the offering, and JMP Securities LLC and RBC Capital Markets, LLC acted as co-managers.
A registration statement relating to the securities sold in this offering was declared effective by the Securities and Exchange Commission on April 11, 2013. Copies of the final prospectus relating to this offering may be obtained by contacting BofA Merrill Lynch by mail at 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or by e-mail at
email@example.com; Credit Suisse Securities (USA) LLC by mail at One Madison Avenue, New York, NY 10010, Attn: Prospectus Department, by e-mail at
firstname.lastname@example.org, or by telephone at 1-800-221-1037; or Jefferies LLC by mail at 520 Madison Avenue, New York, New York 10022, Attn: Equity Syndicate Prospectus Department, by e-mail at
Prospectus_Department@Jefferies.com, or by telephone at 1-877-547-6340.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria.
CONTACT: Allison Wey
Durata Therapeutics, Inc.
Vice President, Investor Relations and Public Affairs